The Food and Drug Administration (FDA) is withdrawing its approval of niacin extended-release (ER) tablets and fenofibric acid delayed release (DR) capsules with cholesterol-lowering statins, saying that based on the outcome of cardiovascular studies on the medications, the benefits of niacin or fenofibric when taken with statins no longer outweigh the risks. The agency concluded that there is no longer scientific evidence that the drugs, when used with statins, reduce triglyceride levels or increase HDL cholesterol levels resulting in a reduced risk of cardiovascular events. Niacin, also known as vitamin B3 and nicotinic acid, and is often used in patients ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.